| P50 | author | Phillip D Stricker | Q59561102 |
| | Nathan Lawrentschuk | Q37830122 |
| P2093 | author name string | James Thompson | |
| | Mark Frydenberg | |
| | Les Thompson | |
| | USANZ | |
| P2860 | cites work | ESUR prostate MR guidelines 2012 | Q24620926 |
| | High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer | Q26996937 |
| | Cancer statistics, 2012 | Q27860574 |
| | Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal--pelvic phased-array coils | Q28241563 |
| | Prospective Assessment of Prostate Cancer Aggressiveness Using 3-T Diffusion-Weighted Magnetic Resonance Imaging–Guided Biopsies Versus a Systematic 10-Core Transrectal Ultrasound Prostate Biopsy Cohort | Q29037865 |
| | Screening and prostate-cancer mortality in a randomized European study | Q29617485 |
| | Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study | Q30514532 |
| | Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy | Q30983669 |
| | Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer | Q33384284 |
| | Intensity-modulated Radiotherapy With Simultaneous Integrated Boost to Dominant Intraprostatic Lesion | Q61731354 |
| | Impact of Multiparametric Endorectal Coil Prostate Magnetic Resonance Imaging on Disease Reclassification Among Active Surveillance Candidates: A Prospective Cohort Study | Q62778197 |
| | MAGNETIC RESONANCE IMAGING OF CLINICALLY LOCALIZED PROSTATIC CANCER | Q63965984 |
| | Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection | Q63966218 |
| | Dynamic Contrast-enhanced–magnetic Resonance Imaging Evaluation of Intraprostatic Prostate Cancer: Correlation with Radical Prostatectomy Specimens | Q63966229 |
| | Combined T2-Weighted and Diffusion-Weighted MRI for Localization of Prostate Cancer | Q63966352 |
| | Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy | Q63966476 |
| | The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy | Q63966719 |
| | A Study of Diffusion-Weighted Magnetic Resonance Imaging in Men with Untreated Localised Prostate Cancer on Active Surveillance | Q63966739 |
| | Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate | Q71927028 |
| | Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis | Q73111497 |
| | Magnetic resonance imaging of prostatic cancer: does detection vary between high and low gleason score tumors? | Q73567561 |
| | Use of pelvic surface coil MR imaging for assessment of clinically localized prostate cancer with histopathological correlation | Q77320221 |
| | Counseling Men With Prostate Cancer: A Nomogram for Predicting the Presence of Small, Moderately Differentiated, Confined Tumors | Q79130701 |
| | Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils. Local staging accuracy of prostate cancer using endorectal coil MR imaging | Q79197210 |
| | Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging | Q79398017 |
| | Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation | Q80404952 |
| | Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate--a 4-year experience | Q80491705 |
| | Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer | Q80609479 |
| | Endorectal magnetic resonance imaging staging of prostate cancer | Q81095442 |
| | Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined | Q81491948 |
| | Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen | Q82228462 |
| | Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer | Q82871323 |
| | Magnetic resonance imaging does not improve the prediction of misclassification of prostate cancer patients eligible for active surveillance when the most stringent selection criteria are based on the saturation biopsy scheme | Q82984543 |
| | Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients | Q83365428 |
| | Single-session primary high-intensity focused ultrasonography treatment for localized prostate cancer: biochemical outcomes using third generation-based technology | Q83529078 |
| | The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels | Q84211715 |
| | Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management | Q84342649 |
| | Pretreatment Endorectal Coil Magnetic Resonance Imaging Findings Predict Biochemical Tumor Control in Prostate Cancer Patients Treated With Combination Brachytherapy and External-Beam Radiotherapy | Q57392719 |
| | The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis | Q57392760 |
| | Diffusion-Weighted MRI of Peripheral Zone Prostate Cancer: Comparison of Tumor Apparent Diffusion Coefficient With Gleason Score and Percentage of Tumor on Core Biopsy | Q58816456 |
| | Magnetic resonance image-guided biopsies with a high detection rate of prostate cancer | Q58915161 |
| | Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy | Q59649550 |
| | Treatment planning using MRI data: an analysis of the dose calculation accuracy for different treatment regions | Q33621996 |
| | Real-time Virtual Sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data | Q33679272 |
| | Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. | Q33744680 |
| | Advances in magnetic resonance imaging: how they are changing the management of prostate cancer | Q33834982 |
| | Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancer | Q33919001 |
| | What are the outcomes of radical prostatectomy for high-risk prostate cancer? | Q33927594 |
| | Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging | Q33964345 |
| | Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. | Q34291551 |
| | Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? | Q34534796 |
| | Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis | Q34796351 |
| | Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness | Q34995967 |
| | Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging | Q35354750 |
| | Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer | Q35722781 |
| | Comparison of pelvic phased-array versus endorectal coil magnetic resonance imaging at 3 Tesla for local staging of prostate cancer | Q35932176 |
| | Value of the hemorrhage exclusion sign on T1-weighted prostate MR images for the detection of prostate cancer | Q35985579 |
| | Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers | Q36294626 |
| | The changing face of prostate cancer | Q36309672 |
| | Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study | Q36346204 |
| | Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging | Q36434291 |
| | Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging | Q36591016 |
| | Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. | Q36818183 |
| | Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results. | Q36918551 |
| | Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer | Q36928846 |
| | Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. | Q36998577 |
| | Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy | Q37007165 |
| | The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis | Q37054328 |
| | Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings | Q37070047 |
| | Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study | Q37145968 |
| | Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies | Q37149144 |
| | Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance | Q37272887 |
| | The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. | Q37372799 |
| | Clinical stage T1c prostate cancer: evaluation with endorectal MR imaging and MR spectroscopic imaging | Q37404915 |
| | Is it time to consider a role for MRI before prostate biopsy? | Q37427381 |
| | 'Prostatic evasive anterior tumours': the role of magnetic resonance imaging | Q37611898 |
| | MRI for men undergoing active surveillance or with rising PSA and negative biopsies | Q37798723 |
| | EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease | Q37807744 |
| | Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting | Q37825030 |
| | Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer | Q37866554 |
| | Imaging in prostate cancer | Q37875083 |
| | Prostate cancer: multiparametric MR imaging for detection, localization, and staging. | Q37935483 |
| | The emerging role of diffusion-weighted MRI in prostate cancer management | Q37976257 |
| | Use of MR imaging to determine preservation of the neurovascular bundles at robotic-assisted laparoscopic prostatectomy | Q37978528 |
| | Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting | Q39477975 |
| | Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer | Q39481285 |
| | Characterization of low-intensity lesions in the peripheral zone of prostate on pre-biopsy endorectal coil MR imaging | Q39595196 |
| | Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging | Q39614126 |
| | Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients | Q39685186 |
| | The 20-core prostate biopsy as an initial strategy: impact on the detection of prostatic cancer | Q39803711 |
| | The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. | Q39842989 |
| | Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy. | Q40004173 |
| | The role of endorectal magnetic resonance imaging in predicting extraprostatic extension and seminal vesicle invasion in clinically localized prostate cancer | Q40666457 |
| | Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer | Q41686096 |
| | Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging | Q41700680 |
| | Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading | Q41943608 |
| | Registration accuracy for MR images of the prostate using a subvolume based registration protocol | Q42114774 |
| | Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. | Q42419373 |
| | Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy | Q42555504 |
| | Prostate cancer: is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance? | Q43101073 |
| | MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters. | Q43236780 |
| | Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging | Q44386860 |
| | Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging | Q44566113 |
| | Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice | Q44716579 |
| | Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients | Q44885683 |
| | A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion | Q45389556 |
| | Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols. | Q45955121 |
| | Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging | Q46314498 |
| | Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer | Q46539252 |
| | Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread | Q46649617 |
| | Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer | Q47414304 |
| | Saturation prostate biopsy in high risk patients after multiple previous negative biopsies | Q48509720 |
| | Saturation technique does not improve cancer detection as an initial prostate biopsy strategy | Q48735293 |
| | A qualitative approach to combined magnetic resonance imaging and spectroscopy in the diagnosis of prostate cancer | Q49149093 |
| | Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. | Q50904451 |
| | Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. | Q51963017 |
| | MR imaging and sonography of early prostatic cancer: pathologic and imaging features that influence identification and diagnosis. | Q52379065 |
| | Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. | Q52865420 |
| | Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection. | Q53024541 |
| | Is endorectal coil necessary for the staging of clinically localized prostate cancer? Comparison of non-endorectal versus endorectal MR imaging. | Q53464860 |
| | Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. | Q53557589 |
| | Prostate cancer vs. post-biopsy hemorrhage: Diagnosis with T2- and diffusion-weighted imaging | Q57385830 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| | diagnosis | Q16644043 |
| P1104 | number of pages | 15 | |
| P304 | page(s) | 6-20 | |
| P577 | publication date | 2013-11-01 | |
| P1433 | published in | BJU International | Q4835773 |
| P1476 | title | The role of magnetic resonance imaging in the diagnosis and management of prostate cancer | |
| P478 | volume | 112 Suppl 2 | |